Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) posted Q4 FY26 revenue of Rs14,611.8cr and net profit Rs2,723.7cr, drove FY26 revenue Rs58,462.0cr with low leverage, won ANVISA clearance for once-weekly semaglutide in Brazil via Hypera, and secured Organon shareholder approval as the acquisit…
Q1 FY 2027 saw 10.1% sales growth, margin expansion, and strong India and innovative medicine performance, offset by U.S. generics decline. Organon acquisition is progressing, with related costs impacting results. Management maintains high single-digit growth guidance.Based on Sun Pharmaceutical In…
Sun Pharmaceutical (NSE:SUNPHARMA) won South African approval to ship generic semaglutide pens for adults with uncontrolled type 2 diabetes in days, while analysts flag the stock as a Buy with a 2,080 target amid a weekly uptrend and 1,880 near‑term support.Previous Week Recap This is a…
